NCT00370357View on ClinicalTrials.gov

SPL7013 Gel - Male Tolerance Study

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

June 30, 2007

Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRUG

3% w/w SPL7013 Gel (VivaGel™)

Trial Locations (1)

3053

Melbourne Sexual Health Centre, Carlton

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Starpharma Pty Ltd

INDUSTRY

NCT00370357 - SPL7013 Gel - Male Tolerance Study | Biotech Hunter | Biotech Hunter